Report Detail Page

Annual ryegrass toxicity vaccine commercialisation plan - WP383

Efforts to attract a commercial partner to develop the Annual Rye Grass Toxicity (ARGT) vaccine have not been successful. The key obstacle is the limited size of the market. The disease is primarily confined to sheep in WA while the technology appears to have no wider application.


Title Size Date published
203.5KB 26/06/2014


Contract No. Title Start date End date Funding type
Annual Ryegrass Toxicity Vaccine Commercialistation Plan - WP383
15/10/2008 15/11/2009

This page was last updated on 06/07/2018

Join myMLA today

One username and password for key integrity and information Systems (LPA/NVD, NLIS, MSA & LDL).

A personalised online dashboard that provides news, weather, events and R&D tools relevant to you.

Customised market information and analysis.

Learn more about myMLA

myMLA Sign Up

Already registered for myMLA?

Sign in here